Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H5A0 | ISIN: US76243J1051 | Ticker-Symbol: 1RV
Tradegate
31.03.25
21:18 Uhr
48,800 Euro
-1,700
-3,37 %
1-Jahres-Chart
RHYTHM PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RHYTHM PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
48,95049,08522:04
0,0000,00022:00

Aktuelle News zur RHYTHM PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoRhythm Pharma stock holds $81 target, Market Outperform rating2
24.03.Finanzvorstand von Rhythm Pharmaceuticals verkauft Aktien für 18.655 US-Dollar4
24.03.Analyst Expectations For Rhythm Pharmaceuticals' Future2
20.03.Rhythm Pharmaceuticals regains rights to obesity drug in China2
20.03.Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE (setmelanotide) in China with Termination of Agreement with RareStone Ltd.81BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...
► Artikel lesen
20.03.RHYTHM PHARMACEUTICALS, INC. - 8-K, Current Report2
19.03.Rhythm Pharmaceuticals gets Orphan Drug status for its hypothalamic obesity treatment in Japan1
19.03.Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan84BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...
► Artikel lesen
RHYTHM PHARMACEUTICALS Aktie jetzt für 0€ handeln
18.03.Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration104BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...
► Artikel lesen
07.03.Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts4
06.03.Citizens JMP maintains Rhythm Pharma Outperform, $81 target2
05.03.Raymond James maintains RYTM stock Outperform rating, $80 target5
03.03.Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, HC Wainwright Analyst Says3
28.02.RHYTHM PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans1
28.02.RHYTHM PHARMACEUTICALS, INC. - 10-K, Annual Report1
27.02.Citizens JMP raises Rhythm Pharma stock target to $813
26.02.Rhythm Pharmaceuticals GAAP EPS of -$0.72 misses by $0.01, revenue of $41.83M beats by $3.35M3
26.02.RHYTHM PHARMACEUTICALS, INC. - 8-K, Current Report-
20.02.Rhythm Pharmaceuticals CEO David Meeker verkauft Aktien im Wert von 566.249 US-Dollar11
20.02.Vorstand von Rhythm Pharmaceuticals veräußert Aktien im Wert von 116.442 US-Dollar7
Seite:  Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1